Cardinal Health Inc NYSE:CAH Price, Chart, News & Insight

Cardinal Health Stock Edges Higher as Strong Q4 Earnings and Bullish FY2027 Outlook Support Shares

Cardinal Health (NYSE: CAH) shares gained about 0.45% on Tuesday after the healthcare distributor reported strong fiscal fourth-quarter results, raised its earnings trajectory for fiscal 2027 and announced a substantial expansion of its share repurchase authorization.

Fourth-quarter revenue increased 6% year over year to $63.7 billion, while GAAP diluted EPS jumped 70% to $1.70. Non-GAAP EPS rose 40% to $2.91, although the figure included a $0.31 benefit from the recognition of IEEPA tariff refunds. Excluding that one-time impact, adjusted EPS still increased a solid 25% to $2.60.

For the full fiscal year, revenue climbed 14% to $254.2 billion, while non-GAAP operating earnings increased 30% to $3.6 billion. Adjusted EPS rose 37% to $11.26, or 33% excluding the tariff-refund benefit.

Pharmaceutical Business Drives Profit Growth

Cardinal Health’s Pharmaceutical and Specialty Solutions segment remained a key earnings driver. Quarterly revenue increased 6% to $58.8 billion, supported by higher brand and specialty pharmaceutical sales, while segment profit jumped 21% to $645 million.

The Global Medical Products and Distribution business presented a more mixed picture. Revenue declined 2% to $3.1 billion, but segment profit more than doubled to $150 million, largely reflecting the IEEPA tariff refunds.

The company's other businesses also remained strong, with revenue increasing 7% and segment profit rising 14%, supported by OptiFreight Logistics and at-Home Solutions.

Cardinal Health Targets Double-Digit EPS Growth in FY2027

The outlook was another positive element of the report. Cardinal Health expects fiscal 2027 non-GAAP EPS of $12.40 to $12.60, representing growth of 13% to 15% and exceeding its longer-term EPS growth framework.

Pharmaceutical and Specialty Solutions profit is expected to grow 8% to 11%, while the company's other businesses are projected to deliver 15% to 18% profit growth. Adjusted free cash flow is forecast at $3.5 billion to $4.0 billion.

Shareholder returns also remain a priority. Cardinal Health repurchased $1.4 billion of shares during fiscal 2026, and its board approved an additional $5 billion authorization, bringing total available repurchase authorization to $6.4 billion as of August.

The relatively modest 0.45% stock gain suggests much of Cardinal Health's strong operating momentum may already be reflected in its valuation. Still, double-digit profit growth across all five operating segments, strong cash generation and above-trend FY2027 EPS guidance provided fundamental support for the shares.

💬

The Investor 08-11-26

Cardinal Health announced a significant expansion of its Actinium-225 (Ac-225) production capacity to support the growing demand for advanced cancer therapies.

The company has added a high-capacity production line at its Center for Theranostics Advancement in Indiana, substantially increasing its supply of cGMP-compliant Ac-225, a key radioactive material used in targeted alpha therapies. These therapies are emerging as a promising treatment option for multiple cancers, including prostate, breast, and lymphoma.

Since 2024, Cardinal Health has already quadrupled its weekly Ac-225 output and expects further increases in 2026 as demand accelerates. The expanded capacity aims to address global supply constraints that have slowed clinical progress in this field.

The company said the move will enhance access for research and clinical trials, where its Ac-225 has already supported more than 15 studies worldwide, positioning it to meet future commercial demand for next-generation cancer treatments.
PRNewswire

💬

Global Finance News 04-03-26

Cardinal Health (NYSE: CAH) has released its 2026 Biosimilars Report, highlighting more than $56 billion in U.S. healthcare savings generated by biosimilars since 2015 and growing provider confidence in their use.

Based on insights from 101 physician practices nationwide, the report shows nearly 99% of providers are comfortable explaining biosimilars to patients. Reimbursement stability remains a key factor in adoption, with 68% of practices rating consistent reimbursement as very important and 59% favoring fixed discount models over variable price reductions.

Oncology continues to lead in biosimilar adoption, with products reaching an average 81% market share within five years of launch. Cardinal Health expects nearly 25 new biosimilars to gain FDA approval over the next two years across immunology, oncology and retina therapies.

The report estimates that under supportive market and policy conditions, biosimilars could generate up to $181 billion in future savings while expanding patient access.

Source: PR Newswire, February 24, 2026.

💬

Global Finance News 02-24-26

Cardinal Health (NYSE: CAH) announced that its Board of Directors approved a quarterly dividend of $0.5107 per share, payable from capital surplus.

The dividend will be paid on April 15, 2026 to shareholders of record as of the close of business on April 1, 2026.

💬

WS Investor 02-13-26

Cardinal Health reported strong second-quarter fiscal year 2026 results, with revenue rising 19% year over year to $65.6 billion. GAAP operating earnings increased 29% to $707 million, while GAAP diluted EPS grew 19% to $1.97. On a non-GAAP basis, operating earnings climbed 38% to $877 million and diluted EPS rose 36% to $2.63, supported by higher segment profits and a lower share count, partly offset by higher financing costs. Reflecting this performance, Cardinal Health raised its fiscal 2026 non-GAAP EPS guidance to a range of $10.15–$10.35, completed its annual $750 million baseline share repurchase, and reached its targeted leverage range.

Source: PRNewswire

💬

WS Investor 02-06-26

Cardinal Health highlighted decades of innovation in biopharma logistics and packaging, underscoring how its Third-Party Logistics Services and Cardinal Health Packaging Solutions teams support the delivery of complex therapies from FDA approval to patient care. The company said the combined capabilities of the two units help biopharma manufacturers manage temperature-sensitive and time-critical treatments, including cell and gene therapies, through advanced packaging, cold chain expertise and integrated logistics.

Cardinal Health noted that the teams have expanded their infrastructure, digital tools and regulatory-compliant services to meet growing industry demands, processing more than 25,000 cell and gene therapy orders since 2017. The company also plans to open a new Midwest distribution center within the next two years to further strengthen its biopharma supply chain network.

Source: Cardinal Health Newsroom, January 22, 2026

💬

The Investor 01-22-26

Dividend Growth Stocks: Cardinal Health, Inc. (CAH) Dividend Stock Analysis

Your source for finding the best dividend growth stocks

(dividend-growth-stocks.com)

💬

Global Finance News 01-17-26

Cardinal Health announced the launch of ContinuCare™ Pathway, a pharmacy-to-supplier referral program designed to simplify access to diabetes supplies covered under medical benefits, including continuous glucose monitors. The program enables pharmacies to refer patients to Cardinal Health at-Home Solutions for direct-to-patient home delivery, reducing administrative burden and supporting continuity of care. Publix Super Markets Inc. has enrolled its nearly 1,400 pharmacies nationwide in the program.

💬

The Investor 01-13-26

Cardinal Health raised its fiscal 2026 outlook and highlighted strategic progress during its presentation at the J.P. Morgan Healthcare Conference.

The company increased its fiscal 2026 non-GAAP diluted EPS guidance to at least $10.00, up from a prior range of $9.65–$9.85, citing strong performance across its operating segments. Cardinal Health also expects Specialty revenues to exceed $50 billion in fiscal 2026, implying a 16% three-year CAGR, driven by specialty distribution growth and rapid expansion in BioPharma Solutions.

In addition, the company confirmed a smooth transition related to the 2026 Medicare Drug Price Negotiation Program and introduced its ContinuCare™ Pathway, a new direct-to-patient program for diabetes supplies, supported by a nationwide partnership with Publix Super Markets.

💬

The Investor 01-13-26

Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2026 on February 5, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

💬

The Investor 01-06-26

NYSE:CAHFollow

Dividend Growth Stocks: Cardinal Health, Inc. (CAH) Dividend Stock Analysis

NYSE:CAH